FDA Explains Why It Rejected Vanda's Stomach Drug in Late 2024

The FDA has detailed its reasons for rejecting Vanda's stomach drug towards the end of 2024. This decision was highlighted in a report by Endpoints News, which focuses on the pharmaceutical and biotech industries. The article did not delve into specific details regarding the FDA's rationale for the rejection, nor did it provide information on the nature of Vanda's stomach drug or the clinical trials it underwent. The report primarily served as a notice of the FDA's decision without elaborating on the technical or scientific grounds for the rejection.